Endocrinol Metab.  2019 Mar;34(1):23-28. 10.3803/EnM.2019.34.1.23.

Search for Novel Mutational Targets in Human Endocrine Diseases

• Park SY
• Seo MH
• Lee S

• KMID: 2441675
• DOI: http://doi.org/10.3803/EnM.2019.34.1.23

Abstract

The identification of disease-causing genetic variations is an important goal in the field of genetics. Advancements in genetic technology have changed scientific knowledge and made it possible to determine the basic mechanism and pathogenesis of human disorders rapidly. Many endocrine disorders are caused by genetic variations of a single gene or by mixed genetic factors. Various genetic testing methods are currently available, enabling a more precise diagnosis of many endocrine disorders and facilitating the development of a concrete therapeutic plan. In this review article, we discuss genetic testing technologies for genetic endocrine disorders, with relevant examples. We additionally describe our research on implementing genetic analysis strategies to identify novel causal mutations in hypocalcemia-related disorders.

Keyword

Genes; Mutation; Endocrinology; Genomics; High-throughput nucleotide sequencing

MeSH Terms

Diagnosis
Endocrine System Diseases*
Endocrinology
Genetic Testing
Genetic Variation
Genetics
Genomics
High-Throughput Nucleotide Sequencing
Humans*

Reference

1. Terry SF, Chappelle A, Burke BC, Christensen K, Garrison A, Hawkins A, et al. Understanding genetics: a New York, Mid-Atlantic guide for patients and health professionals. Washington, DC: Genetic Alliance;2010. p. 6–13.

2. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97:2990–3011.

3. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. Nat Rev Genet. 2006; 7:277–282.

4. De Sousa SM, Hardy TS, Scott HS, Torpy DJ. Genetic testing in endocrinology. Clin Biochem Rev. 2018; 39:17–28.

5. Milunsky A. The “New Genetics” in clinical practice: a brief primer. J Am Board Fam Med. 2017; 30:377–379.

6. Toft M. Advances in genetic diagnosis of neurological disorders. Acta Neurol Scand Suppl. 2014; 129(S198):20–25.

7. Shah MS, Cinnioglu C, Maisenbacher M, Comstock I, Kort J, Lathi RB. Comparison of cytogenetics and molecular karyotyping for chromosome testing of miscarriage specimens. Fertil Steril. 2017; 107:1028–1033.

8. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet. 2013; 14:307–320.

9. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011; 12:745–755.

10. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74:5463–5467.

11. Metzker ML. Emerging technologies in DNA sequencing. Genome Res. 2005; 15:1767–1776.

12. Hyman ED. A new method of sequencing DNA. Anal Biochem. 1988; 174:423–436.

13. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem. 1996; 242:84–89.

14. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998; 281:363–365.

15. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 2014; 30:418–426.

16. Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med. 2018; 379:1353–1362.

17. Persani L, de Filippis T, Colombo C, Gentilini D. Genetics in endocrinology: genetic diagnosis of endocrine diseases by NGS. Novel scenarios and unpredictable results and risks. Eur J Endocrinol. 2018; 179:R111–R123.

18. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Unlocking Mendelian disease using exome sequencing. Genome Biol. 2011; 12:228.

19. Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. JAMA Neurol. 2015; 72:1424–1432.

20. de Bruin C, Dauber A. Insights from exome sequencing for endocrine disorders. Nat Rev Endocrinol. 2015; 11:455–464.

21. Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015; 22:745–757.

22. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018; 19:253–268.

23. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 2014; 99:E1784–E1792.

24. De Sousa SM, McCabe MJ, Wu K, Roscioli T, Gayevskiy V, Brook K, et al. Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours. Eur J Endocrinol. 2017; 176:635–644.

25. Abate EG, Clarke BL. Review of hypoparathyroidism. Front Endocrinol (Lausanne). 2017; 7:172.

26. Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016; 101:2300–2312.

27. Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011; 26:2317–2337.

28. Clarke BL, Brown EM, Collins MT, Juppner H, Lakatos P, Levine MA, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016; 101:2284–2299.

29. Park SY, Eom YS, Choi B, Yi HS, Yu SH, Lee K, et al. Genetic and clinical characteristics of Korean patients with isolated hypoparathyroidism: from the Korean Hypopara Registry study. J Korean Med Sci. 2013; 28:1489–1495.

30. Yi HS, Eom YS, Park IeB, Lee S, Hong S, Juppner H, et al. Identification and characterization of C106R, a novel mutation in the DNA-binding domain of GCMB, in a family with autosomal-dominant hypoparathyroidism. Clin Endocrinol (Oxf). 2012; 76:625–633.

31. Park SY, Mun HC, Eom YS, Baek HL, Jung TS, Kim CH, et al. Identification and characterization of D410E, a novel mutation in the loop 3 domain of CASR, in autosomal dominant hypocalcemia and a therapeutic approach using a novel calcilytic, AXT914. Clin Endocrinol (Oxf). 2013; 78:687–693.

32. Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, et al. A homozygous [Cys25]PTH(1-84) mutation that impairs PTH/PTHrP receptor activation defines a novel form of hypoparathyroidism. J Bone Miner Res. 2015; 30:1803–1813.

33. White AD, Fang F, Jean-Alphonse FG, Clark LJ, An HJ, Liu H. Ca2+ allostery in PTH-receptor signaling. Proc Natl Acad Sci U S A. 2019; 116:3294–3299.

34. Bae J, Choi HS, Park SY, Lee DE, Lee S. Novel mutation in PTHLH related to brachydactyly type E2 initially confused with unclassical pseudopseudohypoparathyroidism. Endocrinol Metab (Seoul). 2018; 33:252–259.